Aerpio Pharmaceuticals EBIT

Aerpio Pharmaceuticals (ARPO) currently reports a EBIT of $-85M as of June 2026. That compares with $-120M in the prior-year period — up 29.2% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Aerpio Pharmaceuticals's EBIT history and peer comparisons.

Aerpio Pharmaceuticals's EBIT increased from $-120M to $-85M — a 29.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aerpio Pharmaceuticals's EBIT of $-85M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aerpio Pharmaceuticals reported $-85M in EBIT as of June 2026. That compares with $-120M in the prior-year period — up 29.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-85M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Aerpio Pharmaceuticals, and consider following ARPO for alerts when major investors trade the stock.